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BACKGROUND: A family history of prostate cancer (PrCa) is a strong risk factor for the disease, indicating that inherited factors are
important in this disease. We previously estimated that about 2% of PrCa cases diagnosed p55 years harbour a BRCA2 mutation and
PrCa among BRCA2 carriers has been shown to be more aggressive, with poorer survival.
METHODS: To further evaluate the role of BRCA2 in PrCa predisposition, we screened 1864 men with PrCa aged between 36 and 88
years. We analysed the BRCA2 gene using a novel high-throughput multiplex fluorescence heteroduplex detection system developed
for the ABI3130xl genetic analyzer.
RESULTS: We identified 19 protein-truncating mutations, 3 in-frame deletions and 69 missense variants of uncertain significance (UV) in
our sample set. All the carriers of truncating mutations developed PrCa at p65 years, with a prevalence of BRCA2 mutation of 1.20%
for cases in this age group.
CONCLUSION: Based on the estimated frequency of BRCA2 mutations in the United Kingdom we estimate that germline mutations in
the BRCA2 gene confer an B8.6-fold increased risk of PrCa by age 65, corresponding to an absolute risk of B15% by age 65. These
results suggest that routine testing of early onset PrCa cases for germline BRCA2 mutations will further help to refine the prevalence
and risk associated with BRCA2 mutations and may be useful for guiding management options.
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Prostate cancer (PrCa) is the most common cancer in men living in
the Western world, with a lifetime risk of B1 in 8 for men in
Europe and the United States (http://info.cancerresearchuk.org/
cancerstats/types/prostate/). Its aetiology remains poorly under-
stood and although many men will not develop a clinically relevant
disease, it is recognised that some PrCa cases have a particularly
poor prognosis. Although there are some histological and stage
predictors of prognosis (Ross et al, 2002), multiple aetiologies,
both hereditary and environmental, have been proposed to
contribute to the development of PrCa. There is strong evidence
that inherited genetic factors are important due to the significant
familial aggregation of the disease in some men, particularly those
affected at a young age (Edwards and Eeles, 2004). Some family
studies have found an increased risk of PrCa among the relatives of
breast cancer patients, suggesting a common genetic basis
(Thiessen, 1974; Anderson and Badzioch, 1992; Tulinius et al,
1992). Clearer evidence has emerged of an increased risk of PrCa in
carriers of BRCA1 and BRCA2 mutations ascertained via family
history of breast cancer (Sigurdsson et al, 1997; Ford et al, 1994).
Analyses of male mutation carriers in breast cancer families from
the Breast Cancer Linkage Consortium (BCLC) found a relative
risk (RR) of 4.65 (95% CI 3.48–6.22) of PrCa in male BRCA2
mutation carriers rising to 7.33 below the age of 65 years and RR
1.07 (0.75–1.54) in BRCA1 mutation carriers with a RR rising to
1.82 (1.01–3.29) for men under 65 years old (Thompson and
Easton, 2001; Thompson and Easton, 2002). Furthermore, through
an analysis of early onset PrCa cases, we previously estimated that
the RR of PrCa in BRCA2 mutation carriers was B23-fold below
age 56 (Edwards et al, 2003). Studies have been conducted in the
Ashkenazi population investigating the association of the BRCA2
6174delT founder mutation with PrCa (Hamel et al, 2003). These
have reported conflicting data and the majority of these studies
have been limited by relatively small sample sizes and did not look
for mutations other than the 6174delT founder mutation.
A study from Iceland reported that PrCa occurring in BRCA2
mutation carriers were more aggressive than those in non-carriers,
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sand had poorer survival (Sigurdsson et al, 1997). These individuals
all carried a common founder mutation (999del5). Narod et al
(2008) reported that survival from PrCa in BRCA2 mutation
carriers is shorter (median survival from diagnosis: 4 years) when
compared with PrCa survival in BRCA1 carriers (median survival
from diagnosis: 8 years). In PrCa where BRCA2 germline mutation
status was unknown, allelic loss at the BRCA2 locus has been
shown to be a prognostic factor for survival on univariate analysis
(Edwards et al, 1998) implying a tumour suppressor mechanism
for BRCA2 and thus predisposition to this disease in BRCA2
mutation carriers, but at that time it was not known if this is a
surrogate for high tumour grade or due to the mutation per se
(Willems et al, 2008). Recent data have shown that it is the
mutation per se that is an independent prognostic factor for PrCa
survival (Edwards et al, 2010b). This was also supported by an
Australian study reporting a very similar finding (Thorne et al,
2011). Here we report a large study of nearly 2000 PrCa cases with
varying ages of diagnosis to validate the potential association
between germline BRCA2 mutation and increased risk of disease
and to refine RR for PrCa among BRCA2 mutation carriers.
MATERIALS AND METHODS
Samples
A series of men with PrCa were recruited from the UK Genetic
Prostate Cancer Study (UKGPCS) as reported previously (Eeles
et al, 1997) and about 90% of these patients had clinically
presenting (non-screen-detected) disease at diagnosis. Case selec-
tion for this study was based predominantly on age of disease
onset p65 (1621 cases; range 36–65 years), with a further cohort
aged 465 but with a family history of one or more first-degree
relatives with PrCa (243 cases; range 66–88 years) selected to
delineate the contribution of germline BRCA2 mutations to PrCa
(Table 1).
Mutation detection
Germline DNA was obtained from peripheral blood samples and
extracted as reported in previous articles (Edwards et al, 1997).
The full coding region and exon–intron boundaries of BRCA2
were analysed using a high-throughput multiplex fluorescent
heteroduplex analysis method. The PCR reactions were performed
using the three-primer system described by NGRL Wessex (http://
www.ngrl.co.uk/Wessex/downloads) and labelled with one of four
dyes (FAM, VIC, NED, ROX). The PCR fragments were diluted 1:50
in H2O and pooled robotically into multiplex groups of up to 8
before mutation screening. These multiplexes were designed using
a range of fragment sizes to prevent overlap of tags with interfering
absorbance spectra. The BRCA2 PCR primer set used was a
modification of that described by NGRI Wessex with alterations to
enhance high throughput. This panel consisted of 46 PCR
fragments, with larger exons covered by multiple overlapping
fragments to ensure mutation detection within the primer regions.
The primer sequences, dyes assigned to each fragment, PCR
conditions and multiplexing information are available on request.
Multiplexed, dye-tagged PCR fragments were run on an
ABI3130xl Genetic Analyzer in 1 TTE running buffer, using a
polymer comprising of 4.5% POP Conformational Analysis
Polymer (CAP–Applied Biosystems, Carlsbad, CA, USA, P/N
4340379), 4 M urea and 1% TTE buffer. Polymer was filtered
through a 0.5-mm filter before use and stored at 41C for up to 1
month. Fragments were analysed for peak shifts corresponding to
putative mutations in Genemapper v4.0 (Applied Biosystems) by
visual inspection and using Bionumerics (Applied Maths,
Sint-Martens-Latem, Belgium).
After confirmation of a peak shift, the samples were re-amplified
by PCR from stock DNA and the genetic alteration was
characterised by sequencing on an ABI3730 Genetic Analyzer with
both forward and reverse PCR primers.
Statistical methods
Confidence intervals for the prevalence of BRCA2 mutations
among PrCa cases were computed using an exact binomial
procedure.
Estimates for BRCA2 prevalence in the general population were
derived from previous studies and used to obtain indirect
estimates of the RR of PrCa in BRCA2 mutation carriers (Antoniou
et al, 2004). Age-specific cumulative risks of PrCa to age 65 in
BRCA2 mutation carriers were computed based on the RR
estimated from this study and age-specific pooled incidence rates
from five cancer registries in England for the year 2002 as reported
in (Ferlay et al, 2007).
Test of differences between carriers and non-carriers in the
family history and age cohorts were performed using Fisher’s exact
test. All statistical analyses were performed using STATA v.10
statistical software (STATA Corp., College Station, TX, USA).
RESULTS
We screened 1864 PrCa cases for germline mutations in the BRCA2
gene. After quality control we excluded 32 samples (all aged p65)
from the analysis. In the 1832 samples analysed we have identified
19 protein-truncating mutations, of which 16 were frameshift and 3
were nonsense mutations (Table 1). Of these deleterious muta-
tions, 16 have been reported previously in breast and ovarian cases
and these are listed on the Breast Cancer Information Core (BIC)
database (http://research.nhgri.nih.gov/bic/), whereas 3 mutations
were novel. In addition, we identified 3 in-frame deletions
(1 novel) and 69 missense variants (13 novel) of uncertain
significance (UV) (Supplementary Table 2), one common non-
sense mutation at the 30 end of the protein (rs11571833), which is
considered to be benign, 31 synonymous substitutions (5 novel)
and 35 intronic variants. All the deleterious mutations were
present in younger onset cases with age of disease diagnosis at
Table 1 Age range and family history of prostate cancer samples screened for BRCA2 germline mutation
Age range,
years
Number of
samples
With family
history of
PrCa (%)
With family
history of
Br/OvCa (%)
Percentage
of samples
deceased
Number of
mutation
carriers
Percentage
of mutation
carriers
Percentage of
mutation carriers
deceased
36–55 632 (34.5%) 34.5 25.3 15.3 8 1.27 37.5
56–65 957 (52.2%) 50.6 24.3 12.4 11 1.15 81.8
66–88 243 (13.3%) 100.0 29.6 29.8 0 – –
Total 1832 51.6 25.4 15.7 19 1.03 63.2
Abbreviations: BrCa¼breast cancer; OvCa¼ovarian cancer; PrCa¼prostate cancer. A total of 1832 samples (age range 36–88) passed quality control, of which 1589 were
aged p65years at diagnosis. Protein-truncating mutations were enriched at younger age of diagnosis. Family history of BrCa and OvCa is also shown.
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cohort diagnosed with PrCa at 465 years old. The deleterious
mutations were found throughout the gene, in exons 10
(4 mutations), 11 (13 mutations), 22 (1 mutation) and 24
(1 mutation) (Figure 1). DNA samples from other family members
were also available for three of the mutation carriers and the
appropriate fragments were sequenced from these relatives. One
case had two affected brothers of whom only one carried the same
mutation (age of onset: 69), one case had one affected brother who
also carried the mutation (age of onset: 54) and in the third family
the case had one affected brother who was not a carrier for the
same mutation (age of onset: 66). Twelve of the deleterious
mutation carriers (12/19) have died with relatively short survival
(1–11 years), eight of these deaths were confirmed to be PrCa
related, the rest are unknown, seven patients are still alive
(Table 2). The majority of the mutation carriers had significant
disease with Gleason score X8 (12 cases, 63%), four cases had
Gleason score p7 and for three patients no data were available
(Table 2) indicating a more aggressive clinical course for the
majority of the BRCA2 mutation carriers.
DISCUSSION
We have analysed the entire coding region and exon–intron
boundaries of the BRCA2 gene from blood DNA of 1864 men
diagnosed with prostate cancer. After quality control we included
1832 DNA samples in our analysis. Of these men, 1589 were
diagnosed at p65 years (Table 1) and the majority presented with
clinical symptoms (data available for 1374 patients, of whom 1218
were clinically detected; 88.6%). The remaining 243 men (PrCa
diagnosed 465 years) had a family history of the disease (at least
one affected first degree relative with PrCa). In the 1832 samples
analysed we identified 19 protein-truncating mutations, which is
likely to be an underestimate of the mutation frequency, as the
mutation detection method we have used (as with other high
through-put methods) would have not been able to detect large
deletions/rearrangements (no MLPA was conducted for this set of
samples). It is also possible that a proportion of the UVs will be
determined to be pathogenic in the future. All 19 deleterious
mutation carriers were affected at p65 years and no mutations
were found in the older onset group with family history, which is
concordant with a previous study (Agalliu et al (2007) where no
association was found between BRCA2 mutation status and high
familial risk of PrCa. Twelve mutation carriers had family history
of PrCa among first- or second-degree relatives (63.2%). This
represents a slight but not statistically significant excess (P¼0.24)
as in the whole study 48.6% of cases p65 had some family history
of PrCa. Nine patients had family history of breast or ovarian
cancer among first- or second-degree relatives (47.4%) and this is
significantly higher than for non-carriers in the study (21.3%,
P¼0.024). Based on these data, the strongest predictors for the
presence of a germline BRCA2 mutation are a young age of onset of
PrCa and a family history of breast and/or ovarian cancer. The
proportion of high-grade PrCa (Gleason score X8) was 63%,
significantly higher than in non-carriers, 15%, (Po0.0001) and
similar results were reported previously by our group and by others
(Edwards et al, 2010a; Gallagher et al, 2010). The clinical and
statistical evaluation of a much larger set of BRCA2 mutation
carrier and non-carrier PrCa cases is underway (Castro et al,
manuscript in preparation). The prevalence of BRCA2 mutations in
this study is 1.27% (8/632) for cases diagnosed p55 years, 1.20%
(19/1589) for cases diagnosed p65 years and 0% (0/243) diagnosed
465 years; P¼0.14. Based on the previously estimated frequency
of BRCA2 mutations in the United Kingdom of 0.16%, we estimated
that germline mutations in the BRCA2 gene confer an increased RR
of PrCa of B8.6-fold (95% CI 5.1–12.6) by age 65 corresponding to
an absolute risk of B15% by age 65 years based on incidence rates
in England from 2002. The estimate of RR from this study is similar
to the 7.3-fold RR from the BCLC study for patients diagnosed
before age 65 years (Thompson and Easton, 2001). Our previous
study reported a higher (B23-fold) RR (Edwards et al, 2003);
although this was calculated from a much smaller cohort of cases all
diagnosed at p55 years old and had a very wide confidence interval
(95% CI 9–57), which overlaps that of this study. This current
study provides more accurate BRCA2 mutation frequencies for
PrCa cases and relative and absolute PrCa risk estimates for BRCA2
mutation carriers.
The protein-truncating mutations identified are situated be-
tween nucleotides 1231 and 9253, predominantly within exons 10
and 11 but not restricted to any specific domain (Figure 1). The
majority, however, are within either the BRC repeat region
(nucleotides 3006–6255), which is responsible for RAD51 binding
or the OB DNA-binding domain (nucleotides 8007–9570), both of
which have an important role in DNA damage repair (Kote-Jarai
and Eeles, 1999; Venkitaraman, 2002).
In addition to the protein-truncating mutations, we identified 3
in-frame deletions and 69 missense UVs (Supplementary Table 1).
We evaluated the missense variants using various predictive tools
(SIFT, polyphen, Align GVGD, pMUT and PANTHER) and
combined these with data available from previous studies on
functional effects of these sequence variants. Although many of
these variants were considered potentially damaging by one or
more programme, but benign by another, the vast majority of the
UVs identified in this study appear to be of little clinical
significance. However, although we cannot rule out a small
proportion being pathogenic, we prefer to take a conservative
approach and only include clearly pathogenic mutations in our
1231delA
1265delA 2807delAACA
2836delGA
1813insA 3158T>G
3405C>A
Exon 10 Exon 11
4478delAAAG
4877delAA
3847delGT
4981delIT
5303delTT
5645C>A
6405delCTTAA
8904delC 9253insA
1787delATGAAACATCTTA
Figure 1 Schematic diagram of the positions of the deleterious mutations found in this study within the BRCA2 transcript. The grey rectangle represents
the BRCA2-coding sequence with exon boundaries marked by vertical black lines. The locations of the BRC repeats are marked in red, the helical domain in
yellow and the three OB domains in green. The ovarian cancer cluster region is represented as a pink rectangle.
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the efforts of groups such as the BIC and ENIGMA (http://
enigmaconsortium.org/) consortia, we can re-examine their role (if
any) in PrCa susceptibility.
In conclusion, we have shown that the frequency of germline
mutation in BRCA2 in PrCa patients is B1.20% at p65 years. No
mutations were found in cases diagnosed 465 in our series,
suggesting that germline BRCA2 mutation is far more closely
linked to a younger age of PrCa onset than to a family history of
PrCa. With the advent of PARPi drugs, which preferentially target
tumours with a BRCA null phenotype (Fong et al, 2009), germline
testing of patients diagnosed at p65 years would be warranted as
part of their cancer care pathway once testing becomes faster and
cheaper.
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